Management Team
-
Dave Marver
Chief Executive Officer
Dave Marver joined ONWARD in July 2020. An accomplished chief executive and director with more than 25 years of international experience in public, private, and emerging companies, he combines expertise in medical and consumer technology, wearables, and health monitoring. Previously, Dave spent almost 15 years with Medtronic in a variety of leadership positions in the US and Europe, including Vice President roles in Sales, Marketing, Strategy, and Business Development. He then joined NASDAQ-listed Cardiac Science Corporation as CEO, before co-founding two start-ups. He holds a BA in Psychology from Duke University and an MBA from University of California Los Angeles. -
Erika Ross Ellison, PhD
VP of Clinical, Regulatory & Quality
Erika Ross Ellison brings extensive expertise in neuromodulation, with experience in clinical trial design and execution for class II and III neurostimulation technologies. She joins ONWARD from Abbott Neuromodulation, where she was Director, Global Clinical & Applied Research. Previously, as Neuroscience Director at Cala Health, she managed the scientific research program that led to de novo clearance and launch of the company’s neurostimulation technology. She also brings outstanding relationships with researchers and clinicians, forged during her years as Deputy Director, Medical Device Innovation Accelerator, Department of Surgery, and Assistant Professor, Department of Neurologic Surgery at Mayo Clinic. Erika holds a BSc in Biology and Business and an MSc in Molecular Biology from the University of Denver and a PhD in Neuroscience from Mayo Clinic. -
Julien Camisani
Vice President, Engineering
Julien Camisani brings more than twenty years of experience, fifteen of which are in the life sciences industry, where he has been instrumental in inventing, developing, marketing, and sustaining advanced laboratory, medical and bio-manufacturing technologies. Prior to joining ONWARD® Medical, Julien led diverse and global teams, and managed large-scale projects with proven leadership across research and development, manufacturing, intellectual property and product management for companies like Cytiva, GE Healthcare and Biosafe. He holds dual master’s degrees in Embedded Systems from the University of Lugano, collaborating with ETH Zurich and Politecnico di Milano, complemented by an MBA from the University of Cumbria and a professional certificate in Technology Road mapping and Strategic Innovation from MIT. -
Bob Odell
Vice President, Operations
Bob Odell brings to ONWARD decades of leadership experience in the medical device industry. Prior to joining ONWARD, Bob was President and Chief Operating Officer of Cardiac Insight, Inc., a successful startup that introduced disruptive technology to the global marketplace. Prior to Cardiac Insight, he served as COO for Cardiac Science, a publicly traded manufacturer of Class II and Class III devices. Bob has held executive assignments in Operations, Engineering, Marketing, Business Development. Information Technology and General Management with such notables as GE Healthcare, Siemens Medical Solutions, Philips Medical Systems, Medtronic, and Analogic. The foundation for his career is a degree in electrical and computer engineering from Syracuse University.
-
Amori Fraser
Finance Director
Amori Fraser serves as the Finance Director at ONWARD Medical, leveraging over 18 years of experience in both finance and auditing. Prior to her current role, she worked as a Senior Manager at EY, specializing in financial reporting, regulatory compliance, financial analysis and internal controls serving multi-national listed groups. Amori's experience in auditing and finance enables her to drive efficient financial operations and support the company’s growth initiatives. Amori holds a BComHons degree in Accounting Sciences from the University of Pretoria and is a qualified Chartered Accountant (CA) with the South African Institute of Chartered Accountants (SAICA).
-
Alexandre Casteau
Head of Strategy & Corporate Development
Alexandre Casteau brings extensive healthcare corporate strategy expertise. A former management consultant with McKinsey & Company, Alexandre spent several years advising global life science businesses on growth strategy and large-scale transformations. He also launched and led the McKinsey Switzerland startup/scaleup service line, providing a differentiated strategy consulting offering to help early-stage, fast-growing companies scale. Earlier in his career, Alexandre held a variety of roles at Endeavor, Rocket Internet SE and Société Générale Corporate & Investment Banking. He holds an MBA from INSEAD and an MSc. from MIT. -
Julie Crom
Director, People & Culture
Julie Crom has more than 10 years of experience in Human Resources in the medical devices industry. Prior to joining ONWARD Medical, Julie served as Healthcare & Life Sciences Practice Lead at Michael Page, a leading recruitment company in Europe. In her role, she supported middle-to-large medical device companies in recruitment and organizational strategy. Julie holds an MSc in International Business Management from INSEEC business school. -
Lorenzo Fanti
Vice President, Legal
Lorenzo Fanti is a dual-qualified US and English attorney with nearly 15 years of experience specializing in pharmaceuticals and medtech. Prior to joining ONWARD Medical, Lorenzo served as worldwide Legal Head, Ophthalmology ad interim at Novartis Pharmaceuticals, and, prior to that, he was Country Legal Head for Chile ad interim for the Novartis group of companies. He has held various roles with increasing responsibility at Novartis, including in the Neuroscience franchise, where he contributed to the launch of innovative migraine treatments. Early in his career, he was a Trademark Paralegal with Sandoz, and he trained with Allen & Overy LLP in London. He holds an LL.B. from the University of Wales.
Board Members
-
Rob ten Hoedt
Board Chair and Non-Executive Director
Rob ten Hoedt is Chairman and a Non-Executive Director of ONWARD since 2024. He was previously Executive Vice President & President of Global Regions at Medtronic, overseeing the Americas, EMEA, and Asia Pacific. He also served on Medtronic’s Executive Committee. Rob was Chairman of the Board of MedTech Europe, the industry association for medical technology in Europe; he is the current Chairman of Medmix in Switzerland, and serves on the boards of Fagron International and NLC Health. Rob holds a degree in Commercial Economy from H.E.A.O., and a Master's in Marketing from NIMA Business School in the Netherlands. (Rob’s appointment is temporary until formally ratified by shareholders in 2025).
-
John de Koning
Non-Executive Director
John de Koning is a Non-Executive Director of ONWARD since 2016. He is a General Partner at EQT Life Sciences, one of the largest European investment firms providing financing for life sciences and health care companies. Since joining EQT Life Sciences (formerly LSP) in 2006, John has led some of its most successful investments and served on the board of several companies, including argenx, Merus, and Prosensa. John holds an MS in Molecular Biology from the University of Utrecht and a PhD in Oncology from the Erasmus University Rotterdam. -
Kristina Dziekan
Non-Executive Director
Kristina Dziekan is a Non-Executive Director of ONWARD since 2022. She is Head of Market Access, Government Affairs and Tendering for Alcon’s Surgical Division in Europe. Prior to her experience at Alcon, she served as Senior Global Reimbursement and Health Economics Director for Medtronic Neuromodulation and Health Outcomes Manager for GlaxoSmithKline in the UK and parts of Asia. Ms. Dziekan has an MSc in Health Policy, Planning, and Financing from the London School of Economics, an MA in International Economics and European Studies from Johns Hopkins University, a BA in Philosophy, Politics, and Economics from Oxford University and a Vordiplom in Business Administration and Economics from Georg August University. -
Ian Curtis
Non-Executive Director
Ian Curtis is a Non-Executive Director of ONWARD Medical since 2019. Ian is a director of SCI Ventures, a venture capital firm that invests in companies focused on treatments for paralysis. He is a member of the board of the Christopher & Dana Reeve Foundation and the International Spinal Research Trust. Ian is also the chairman of HPC plc, a UK-based engineering company. He is a graduate of Durham University, a fellow of the Institute of Chartered Accountants in England and Wales, and a former partner with PwC. -
Vivian Riefberg
Non-Executive Director
Vivian Riefberg is a Non-Executive Director of ONWARD since 2022. She was formerly a senior partner with McKinsey & Company, where she led the Public Sector Practice for the Americas and was co-leader of the U.S. Health Care practice. Vivian is a Professor at University of Virginia’s Darden School of Business. She previously served on the U.S. National Institutes of Health (NIH) Clinical Center Board of Governors and on the NIH Advisory Board for Clinical Research. Vivian currently serves on the boards of Signify Health, K Health, Lightrock and Johns Hopkins Medicine. She holds a B.A., magna cum laude in history from Harvard-Radcliffe College and an M.B.A. with distinction from Harvard Business School. -
Dave Marver
Chief Executive Officer
Dave Marver joined ONWARD in July 2020. An accomplished chief executive and director with more than 25 years of international experience in public, private, and emerging companies, he combines expertise in medical and consumer technology, wearables, and health monitoring. Previously, Dave spent almost 15 years with Medtronic in a variety of leadership positions in the US and Europe, including Vice President roles in Sales, Marketing, Strategy, and Business Development. He then joined NASDAQ-listed Cardiac Science Corporation as CEO, before co-founding two start-ups. He holds a BA in Psychology from Duke University and an MBA from University of California Los Angeles. -
Grégoire Courtine, PhD
Non-Executive Director
Prof. Grégoire Courtine is the co-founder of ONWARD Medical and a Non-Executive Director. His ground-breaking research in neuroscience has been recognized by several prestigious prizes, including the Rolex Award, the Schellenberg Research Prize and the Chancellor’s Award of the University of California. Grégoire is a full professor of neuroscience and neurotechnology at the Swiss Federal Institute of Technology (EPFL) and Director of NeuroRestore, a research center at EPFL and the University Hospital of Lausanne that develops innovative therapies using neurostimulation and other approaches. He holds a PhD in Neurosciences from INSERM Paris and the faculty of Medicine of the University of Pavia, Italy. -
Rahma Samow
Non-Executive Director
Rahma Samow is a Non-Executive Director of ONWARD since 2024. She is currently President and CEO of ClearChoice Dental Implant Centers, a US-based provider of dental implant therapy and tooth replacement services with over 2,000 employees. Prior to ClearChoice, she served on the Executive Management Board of the Swiss-based Straumann Group. She also had a 15-year career with Siemens Healthineers, where she held various roles in sales, marketing, and communications in their digital health business, with geographic responsibilities spanning the US, Germany, Middle East, and Africa. Ms. Samow holds a Diploma in Medical Radiology, Radiation Therapy, and Nuclear Medicine Technology from the Medical University of Bonn, Germany. (Rahma’s appointment is temporary until formally ratified by shareholders in 2025).
Corporate Governance Overview
The Board of Directors of ONWARD Medical (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations. They are effective as of first day of trading.